FGF10 and Hepatic fibrosis: Hepatocyte-targeted reinforcement of FGFR2 signalling, alone or combined with metabolic therapies, represents a translational strategy to reprogram the fibrotic niche and facilitate fibrosis regression-associated architectural remodelling in advanced liver fibrosis.<h4>Key points</h4>Hepatic FGF10 and FGFR2 decline consistently with fibrosis stage in patient liver biopsies and complementary mouse models.